glp-1 agonists reduce inflammation Frontiers You've heard about GLP-1s for

Diabetes Obes Metab

Research, including recent findings from the SELECT trial, indicates that GLP-1 agonists like semaglutide can significantly reduce the risk of major cardiovascular events, such as heart attacks and strokes, especially in individuals with obesity but without diabetes

However, significant risks and uncertainties accompany off-label low-dose use

GLP-1 is a naturally occurring human hormone, released in the small intestine in response to food, that helps stabilize glucose levels

Clinical Trial Results SURMOUNT-1 trial: Average weight loss of ~20% of total body weight

Gastrointestinal side effects may still occur even at reduced doses